Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qlaris Bio, Inc.
• Treatments: Timolol

Criteria

Inclusion Criteria:

1. Visual acuity +1.0 logMAR or better

2. Willing to give informed consent

3. Ability to washout from current intraocular pressure lowering medications -

Exclusion Criteria:

1. Severe glaucomatous damage

2. Previous glaucoma intraocular or laser surgery

3. Refractive surgery

4. Ocular infection or inflammation